Pavel Raifeld
Known title: Chief Executive OfficerCIK: 0001813426
Pavel Raifeld's purchase track record
Pavel Raifeld has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/10/2023 | INVA | $33K | +23.3% | +17.0% | +15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INVA | ▼ Sell | Tax Withholding | 1,130 | $24K | 8/20/2026 | View on chart |
| INVA | ▼ Sell | Tax Withholding | 1,130 | $25K | 5/20/2026 | View on chart |
| INVA | ▲ Buy | Grant | 1,123 | $0 | 5/15/2026 | View on chart |
| INVA | ▲ Buy | Grant | 126,646 | $0 | 5/4/2026 | View on chart |
| INVA | ▼ Sell | Tax Withholding | 2,986 | $70K | 2/20/2026 | View on chart |
| INVA | ▲ Buy | Grant | 110,436 | $2.0M | 11/3/2025 | View on chart |
| INVA | ▲ Buy | Grant | 1,860 | $0 | 5/15/2025 | View on chart |
| INVA | ▲ Buy | Grant | 37,377 | $650K | 3/14/2025 | View on chart |
| INVA | ▲ Buy | Open Market | 3,000 | $33K | 3/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation
Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation. Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.